July 11, 2023: Ratio Therapeutics, In Collaboration with Lantheus and PharmaLogic, Announce First Patient Dosed in Phase I Study Evaluating a Novel FAP-Targeted Radiopharmaceutical for PET Imaging
A collaboration to advance development of a fibroblast activation protein (FAP)-targeted PET diagnostic compound for a broad array of epithelial-derived cancers.
May 9, 2023: Ratio Therapeutics Announces Opening of New Research and Development Facility
Boston-based fast-growing radiopharmaceutical company opens the doors to its new headquarters and research facility to advance targeted radiotherapies for cancer
March 28, 2023: Ratio Therapeutics Announces Licensing Agreement for Investigational PET Imaging Agent with Merck
Collaboration to develop a Granzyme B-targeted agent for PET imaging applications in inflammation and cancer indications
March 13, 2023: Ratio Therapeutics Appoints Dr. Noel Monks as Head of Biology
Dr. Monks joins Ratio with over 20 years of experience in drug discovery, development, and translational medicine in the fields of oncology and rare diseases.
February 1, 2023: Ratio Therapeutics Announces $20M Series A Financing to Advance Targeted Radiotherapies for Cancer Treatment
Boston-Based Pharmaceutical Company Brings Total Financing to More Than $40 Million since 2022 Launch. Dr. Susan K. Whoriskey, Ph.D., to Join the Company’s Board of Directors as Strategic Advisor.
December 6, 2022: Ratio Therapeutics Appoints Reed Malleck as Chief Financial Officer
Mr. Malleck comes to Ratio with more than 25 years of finance and accounting experience in numerous healthcare and life science companies.
September 15, 2022: Ratio Therapeutics Appoints Jacob Hesterman, Ph.D., as Chief Data Officer
In this newly created role, Dr. Hesterman will build the company’s data management and data sciences infrastructure. In addition to oversight of the data platform, Hesterman will manage imaging and dosimetry for Ratio’s discovery and clinical programs.
July 6, 2022: Eckert & Ziegler Becomes Contract Manufacturer for Clinical Development Candidates Based on Lutetium-177 and Actinium-225
Eckert & Ziegler (ISIN DE0005659700, SDAX) has signed an agreement with the U.S. pharmaceutical company Ratio Therapeutics Inc. for the joint development and manufacture of innovative radiopharmaceutical products based on Lu-177 and Ac-225.
June 10, 2022: Ratio Therapeutics Launches to Discover and Drive Early Clinical Development of Best-in-Class Targeted Radiopharmaceuticals for Treatment of Cancers
Company Emerges from Stealth Mode with More Than $20 Million in Seed Financing and Fully Funded Development Alliances with Bayer and Lantheus.